research

Supreme Court turns down Trump’s plan to cut off UC research grants that promote DEI

The Supreme Court refused Monday to hear an appeal from President Trump and cut off research grants to University of California professors that promote diversity, equity and inclusion.

Without a comment or dissent, the justices turned down the administration’s appeal and let stand a 9th Circuit Court ruling that held the cutoff of these research grants violated the 1st Amendment.

The court’s action is a significant win for the embattled professors and a defeat for Trump.

At issue in the appeal was whether the administration’s plan could cut off about $150 million in UC research grants that were awarded by the National Endowment for Humanities and the National Science Foundation. It was a small part of a larger fight nationwide that could affect several billion dollars in government grants.

When Trump returned to office last year, he issued an executive order “ending radical and wasteful government DEI programs.” He said universities had “adopted and actively use dangerous, demeaning, and immoral race and sex-based preference under the guise” of DEI.

In response, several agencies sent form letters to professors terminating their grants. They did so based on key words in the proposals such as diversity, equity or “environmental justice.”

The researchers were told their projects no longer fit “agency priorities.”

Six UC professors filed a class-action suit to challenge the terminations. They cited constitutional claims including due process of law as well as a violation of government procedures.

But the Supreme Court narrowed the claims in different and much larger cases involving health and education grants. It said claims for canceled grants must go to the Court of Federal Claims and cannot be overturned by a federal judge.

Citing those decisions, the 9th Circuit Court in May limited the UC case to a 1st Amendment claim.

The government may not use “its power to punish or suppress disfavored expression,” the appeals court said.
Its judges agreed the government may choose to fund some programs and not others, but they said officials may not discriminate against qualified grant recipients because of their viewpoint.

Solicitor Gen. D. John Sauer, representing the Trump administration, argued this view of the 1st Amendment was wrong and could limit the government’s authority over spending and grants.

He told the court that “vast sums of taxpayer money are at stake. The UC system took in more than $4 billion in federal grant money in 2024,” he said.

But the justices denied the appeal in Trump vs. Thakur.

UC Berkeley Law Dean Erwin Chemerinsky had urged the court to deny the appeal. Its past decisions make clear that “ideologically driven attempts to suppress a particular point of view are presumptively unconstitutional in funding,” he said.

Source link

Voters approve Prop. 38 medical research bond measure

California voters have passed Proposition 38, authorizing the state to issue $8.4 billion in bonds to fund immunology and immunotherapy research aimed at curing and preventing certain chronic diseases.

The measure, which the Associated Press called on Monday evening, requires at least $4.2 billion of the funds to be used for immunology research on cancer, heart disease and Alzheimer’s disease. It also authorizes the state to enter into a partnership with an unnamed immunology and immunotherapy research institute selected by the California Department of Public Health, and to allocate half of the bond revenue to it.

Opponents argued that the measure would saddle taxpayers with decades of debt and that the requirements to qualify for grants created such a narrow pool of candidates that only one research institute in California, the California Institute for Immunology and Immunotherapy, currently meets the criteria to receive half the bond revenue. Gary K. Michelson, a wealthy philanthropist who wrote the proposition, co-founded the institute. He was also the proposition’s largest supporter, pouring $45 million into the campaign, according to state data.

Remaining funds will be used for competitive research grants that focus on immunology and immunotherapy. Those grants would be awarded by a council of representatives from University of California campuses, universities and nonprofit research institutions.

Supporters celebrated the passage on Monday saying in a press release that it “comes as federal research funding cuts have disrupted clinical trials and delayed medical discoveries nationwide.”

“This victory belongs to the patients and families who have spent years fighting devastating diseases and waiting for the next medical breakthrough,” Chris Tarver, a nurse and president of the American Nurses Association\California, said in a prepared statement.

Californians will take on an increased cost of $500 million to $600 million annually to repay the bond for an anticipated 20 years, according to the Legislative Analyst’s Office. Some or all of the cost could be offset if any funded research generates revenue. However, it’s difficult to predict how many, if any, research projects would lead to marketable treatments.

Times staff writer Hannah Fry contributed to this report.

Source link

California Proposition 38 voter guide: Funding research to prevent and cure diseases

p]:text-cms-story-body-color-text”>

Spearheading the campaign in opposition of Proposition 38 is Robert Kaplan, senior scholar at the Clinical Excellence Research Center at Stanford School of Medicine, and David Panush, who served as a senior health policy and budget advisor to five state Senate presidents.

Kaplan stated, “As written, Proposition 38 is deceptive,” because the proposed criteria for awarding the grant funding would appear to create an extremely minuscule pool of qualified recipients.

To qualify, a recipient institution must be established since Jan. 1, 2025, and have at least 200,000 square feet of research space it controls. From that start date, the recipients also must have an affiliation agreement with a UC campus and be affiliated with a UC Health system that records more than 35,000 inpatient admissions and 3.5 million outpatient visits annually. The qualification requirements also include having identified at least $250 million in philanthropic support and securing two $50-million commitments for designated research programs.

Kaplan argues medical research grants should be awarded through a competitive process that gives all applicants equal opportunity. Instead, his campaign states, only the California Institute for Immunology and Immunotherapy, co-founded by billionaire Gary K. Michelson, would qualify under the proposed criteria. In a Cal Matters report, a UCLA spokesperson confirmed that among all nonprofit entities affiliated with the school, “only the California Institute for Immunology and Immunotherapy could satisfy the stipulations of Prop. 38.”

Robin Swanson, spokesperson for the Yes on 38 campaign, said that “lots of institutions would qualify for funds under this measure.”

“But it is very likely that [the California Institute for Immunology and Immunotherapy], which is a research institute affiliated with UCLA, will qualify for half of the funds under the current criteria,” she added during a virtual news conference in mid-September.

Swanson said it was likely that other research institutions from Stanford, Scripps Research, USC and Cedars Sinai would qualify for the other 50% of funds, “and that really is what we wanted to ensure that we had research institutes that were ready to hit the ground running.”

Ultimately, she said, the decision lies with the California Department of Public Health.

Michelson’s institute first became a nonprofit in 2022, and the co-founder has donated at least $120 million to the research organization. The billionaire is the board chair of the institute, which is housed at a research center owned by UCLA, according to the opposition campaign.

The Vote No on Prop. 38 campaign also argues against the financial model of the measure, saying a bond would saddle taxpayers with decades of debt and that any potential future revenue from the research is uncertain.

Source link

California Prop. 38 last-minute guide: Immunology, immunotherapy research funding

The Trump administration has frozen, terminated or delayed billions in congressionally approved research grants since last year. Proposition 38 aims to backfill some of that loss by creating a stable source of money to fund immunology and immunotherapy research.

The basics

Proposition 38 would authorize the state to issue $8.4 billion in bonds to fund immunology and immunotherapy research to uncover treatments that help the immune system fight diseases such as cancer and Alzheimer’s disease more efficiently.

The impact

The measure would require at least $4.2 billion of the funds to be used for immunology research on cancer, heart disease and Alzheimer’s. It also would authorize the state to enter a partnership with an immunology and immunotherapy research institute selected by the California Department of Public Health and allocate half of the bond revenue to it. The remaining funds would be used for competitive grants that focus solely on immunology and immunotherapy research.

Californians would take on an increased cost of $500 million to $600 million annually to repay the bond for about 20 years, according to the Legislative Analyst’s Office.

The Yes on 38 campaign says the proposition pays for itself: 10% of all proceeds from the licensing of immunotherapies must be returned to the state to offset the total cost of the bond measure, including interest.

However, it’s difficult to predict whether any research projects will lead to marketable treatments.

Dig deeper

Proposition 38 is backed by organizations including the Michael J. Fox Foundation for Parkinson’s Research and the ALS Assn., as well as a majority of local chapters of Democratic organizations across the state. Supporters say the proposed funding could give those afflicted with chronic illness hope and potentially more options for treatment.

Its opponents have said the proposed criteria for awarding the grant funding would appear to create an extremely small pool of qualified recipients. Only the California Institute for Immunology and Immunotherapy, co-founded by billionaire Gary K. Michelson, would qualify under the proposed criteria, according to No on 38, the campaign against the proposition.

Robin Swanson, spokesperson for the Yes on 38 campaign, said “lots of institutions would qualify for funds under this measure.”

But she said at a virtual news conference in mid-September that it was “very likely” that the California Institute for Immunology and Immunotherapy “will qualify for half of the funds under the current criteria.”

Ultimately, Swanson said, the decision lies with the California Department of Public Health.

More reading

Your guide to Proposition 38: Immunology and immunotherapy research funding (L.A. Times)

An analysis of Prop. 38 (California Legislative Analyst’s Office)

This CA proposition will send $4 billion to a single nonprofit. Who’s behind it? (Cal Matters)

This institute could get $4 billion from a ballot measure. With just three workers, is it ready? (Cal Matters)

Source link